I help life sciences, AI architects and global health leaders decide what to advance, who should carry it forward, and which commitments must line up to make it real.
Work out which bets deserve the money, and what evidence should change your mind.
Get the partners, the rights, and the money all pointed at the same next step.
Make sure the rights, the tech transfer, the buyers, and the factory decisions all line up.
Make sure access commitments survive contact with commercial reality.
AI is speeding up discovery. The question is whether the agreements, institutions, and regional capabilities around it can keep pace. Strategy for AI-native biotech, and for the funders adapting to it.
Tell me the goals, decisions, the constraints, and the timing. We’ll figure out where a focused engagement would help, or I’ll tell you it wouldn’t.
A defined objective, clear and achievable deliverables, fixed fee. You get the analysis and the recommendation, not an open-ended meter.
As our plan and any commitments unfold (partnerships, financing rounds, manufacturing decisions), I’m in the room. Quarterly review, 30-day out, no surprises.
Applied a weighted framework to compare human and veterinary vaccine opportunities across a $100M+ portfolio through three action lanes (advance, validate, or hold), giving the executive team and board a defensible basis to fund two, pause several and kill one.
Proposed a partner-led development model (transfer-ready package, early development owner, work allocated by stage) for a Phase 2 vaccine with no commercial owner, unlocking a funded path to potential licensure.
Mapped five agreement tracks against facility readiness, engineering, regulatory preparation, financing, and advance purchase for a regional vaccine manufacturing project, gating a nine-figure build decision while still enabling a successful fast track.
Details anonymized. The decisions were real.
AI may speed vaccine design. The harder test is whether the agreements, institutions, and regional capabilities around it can keep pace. First in a planned series on AI, equitable access, and IP. Read on LinkedIn →
I advise biotechnology and global health organizations on partnerships, financing, and equitable access. I’ve sat on both sides of the table: building regional partnerships inside a vaccine developer (Novavax), then financing and structuring them at CEPI during COVID-19 and the COVAX effort. I bring that experience to the choices facing boards, developers, funders, and investors: what deserves the next commitment, and what needs to be in place before it is made.
These days I’m also advising AI-native biotech companies, and writing about what has to change as AI speeds things up: who gets access, who owns what, and whether the institutions can keep pace.
Tell me the choice, the constraint, and the timing. We can discuss where a focused engagement would help.
